Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLSD 
Clearside Biomedical Inc (CLSD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CLSD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.43
1 Year Target Price $5.43
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.06% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.84M USD | Price to earnings Ratio - | 1Y Target Price 5.43 |
Price to earnings Ratio - | 1Y Target Price 5.43 | ||
Volume (30-day avg) 7 | Beta 2.06 | 52 Weeks Range 0.70 - 1.65 | Updated Date 06/30/2025 |
52 Weeks Range 0.70 - 1.65 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -223.39% |
Management Effectiveness
Return on Assets (TTM) -54.08% | Return on Equity (TTM) -1310.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 48380743 | Price to Sales(TTM) 15.9 |
Enterprise Value 48380743 | Price to Sales(TTM) 15.9 | ||
Enterprise Value to Revenue 12.85 | Enterprise Value to EBITDA -2.84 | Shares Outstanding 77708496 | Shares Floating 67402053 |
Shares Outstanding 77708496 | Shares Floating 67402053 | ||
Percent Insiders 13.02 | Percent Institutions 14.32 |
Analyst Ratings
Rating 3 | Target Price 5.43 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Clearside Biomedical Inc
Company Overview
History and Background
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of therapies for eye diseases. Founded in 2011, it is known for its suprachoroidal space (SCS) injection platform.
Core Business Areas
- Ophthalmology: Develops and commercializes therapies using its proprietary SCS injection platform to treat various eye diseases.
Leadership and Structure
George Lasezkay, MD, is the CEO. The company has a board of directors and operates with typical functional departments like R&D, manufacturing, commercial, etc.
Top Products and Market Share
Key Offerings
- XIPERE: XIPERE (triamcinolone acetonide injectable suspension) is Clearside's primary commercial product, approved for the treatment of macular edema associated with uveitis. Market share data is difficult to ascertain precisely due to varied causes of uveitis. Competitors include steroid treatments and other therapies addressing uveitis-related macular edema. Competitors include AbbVie (Humira), Regeneron (Eylea).
Market Dynamics
Industry Overview
The ophthalmology market is large and growing, driven by aging populations and increased prevalence of eye diseases. Novel drug delivery methods are gaining traction.
Positioning
Clearside's SCS injection platform provides a differentiated approach to drug delivery in the eye, potentially offering improved efficacy and reduced side effects. The company is well-positioned within the niche of uveitis-related macular edema.
Total Addressable Market (TAM)
The global uveitis market is estimated to be in billions of USD. Clearside is targeting a specific subsegment with XIPERE. Market is constantly expanding as the elderly populations are increasing.
Upturn SWOT Analysis
Strengths
- Proprietary SCS injection platform
- FDA-approved product (XIPERE)
- Experienced management team
- Specific focus on niche market
Weaknesses
- Limited product portfolio
- Reliance on a single product for revenue
- Small market capitalization
- Requires specialist for injection
Opportunities
- Expanding indications for SCS injection platform
- Partnerships and collaborations
- Geographic expansion
- Development of new ophthalmology therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- REGN
- SNY
Competitive Landscape
Clearside has a unique drug delivery system but faces intense competition from established players with broader product portfolios and greater resources. XIPERE is only treatment for uveitis related macular edema, however AbbVie and Regeneron treat a wider range of eye problems with more effective treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the development and commercialization of XIPERE.
Future Projections: Future growth will depend on the continued sales growth of XIPERE, expansion into new indications, and potential partnerships.
Recent Initiatives: Recent initiatives include expanding commercialization efforts for XIPERE and advancing other pipeline candidates.
Summary
Clearside Biomedical is a biopharmaceutical company focused on ophthalmology, centered around its suprachoroidal space injection platform. The company's success depends heavily on the sales of its sole commercial product, XIPERE, and its ability to expand into new indications. It faces strong competition from larger pharmaceutical companies. Clearside needs to diversify its product portfolio and secure strategic partnerships to ensure long-term growth. It is also challenged by the specific injection for the drug and other competitors that can treat a wider variety of eye problems.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimates and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearside Biomedical Inc
Exchange NASDAQ | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2016-06-02 | President, CEO & Director Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://clearsidebio.com |
Full time employees 32 | Website https://clearsidebio.com | ||
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.